Bryan Luce1, Rebecca Singer Cohen. 1. United BioSource Corporation, Bethesda, Maryland 20814, USA. bryan.luce@unitedbiosource.com
Abstract
OBJECTIVES: To describe and explore the reasons for the current health technology assessment (HTA) landscape in the United States. METHODS: Relying on multiple historical literature and other documents as well as drawing on personal experiences and observations, we describe, evaluate, and explain the evolving and dynamic HTA-related evidence landscape. RESULTS: The present HTA-related landscape is a product of a dynamic, somewhat turbulent path in the United States. Many early aggressive federal efforts beginning in the 1970s were rejected in the 1980s only to be revived by the mid-1990s and continue to strengthen today, likely due to diffusing private sector political opposition from de-linking HTA from policy decisions (e.g., coverage, clinical guidelines) and omitting economic evaluation. Meanwhile, private sector HTA efforts have remained active during the entire period. CONCLUSIONS: The current HTA-related landscape is at least as dynamic as it has been at any point in its turbulent 30-year history and is likely to continue as health reform in the US is debated once again.
OBJECTIVES: To describe and explore the reasons for the current health technology assessment (HTA) landscape in the United States. METHODS: Relying on multiple historical literature and other documents as well as drawing on personal experiences and observations, we describe, evaluate, and explain the evolving and dynamic HTA-related evidence landscape. RESULTS: The present HTA-related landscape is a product of a dynamic, somewhat turbulent path in the United States. Many early aggressive federal efforts beginning in the 1970s were rejected in the 1980s only to be revived by the mid-1990s and continue to strengthen today, likely due to diffusing private sector political opposition from de-linking HTA from policy decisions (e.g., coverage, clinical guidelines) and omitting economic evaluation. Meanwhile, private sector HTA efforts have remained active during the entire period. CONCLUSIONS: The current HTA-related landscape is at least as dynamic as it has been at any point in its turbulent 30-year history and is likely to continue as health reform in the US is debated once again.
Authors: Alexander C Egilman; Joshua D Wallach; Sanket S Dhruva; Gregg S Gonsalves; Joseph S Ross Journal: J Gen Intern Med Date: 2019-11 Impact factor: 6.473